Penehyclidine and Postoperative Nausea and Vomiting After Bimaxillary Surgery

Peking University

Status: Completed

Conditions: Postoperative Nausea and Vomiting; Penehyclidine; Bimaxillar Surgery

Treatments: Drug: Penehyclidine hydrochloride; Other: No penehyclidine hydrochloride

Study type: Observational

Funder types: Other

Identifiers

NCT04112771

201947098

Details and patient eligibility

About

Postoperative nausea and vomiting (PONV) are common complications after surgery. Patients undergoing orthognathic surgery are reported to have a high rate of PONV, especially those undergoing bimaxillary surgery. Activation of cholinergic system plays an important role in the development of PONV. Penehyclidine is an muscarinic antagonists which selectively block M1 and M3 receptors and is commonly used to decrease oral secretion. The purpose of this retrospective cohort study is to investigate whether use of penehyclidine is associated with a reduced risk of PONV in patients undergoing bimaxillary surgery.

Full description

Postoperative nausea and vomiting (PONV) are one of the most frequent complications after surgery, and are associated with patients' dissatisfaction after anesthesia and surgery. Orthognathic surgery is widely performed for the correction of dentofacial deformities. PONV is common after orthognathic surgery. Despite of improved anti-emetic prophylaxis, patients undergoing orthognathic surgery are reported to have a high incidence of PONV, especially those after bimaxillary surgery.

It is known that activation of central cholinergic system plays an important role in the development of PONV. Muscarinic antagonists such as scopolamine can block muscarinic receptors in the cerebral cortex and produce anti-emetic effects. Penehyclidine is a new muscarinic antagonists which selectively block M1 and M3 receptors. It has fewer adverse effects compared with other anticholinergics. The purpose of this retrospective cohort study is to investigate whether use of penehyclidine is associated with a reduce risk of PONV in patients undergoing bimaxillary surgery.

Enrollment: 243 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age ≥16 years;
• Underwent elective bimaxillary surgery under general anesthesia.

Exclusion criteria

• Age <16 years;
• Missing data.

Trial design

243 participants in 2 patient groups

Penehyclidine group

Description:

Penehyclindine hydrochloride was administered before anesthesia induction.

Treatment:

Drug: Penehyclidine hydrochloride

Placebo group

Description:

Penehyclindine hydrochloride was not administered before anesthesia induction.

Treatment:

Other: No penehyclidine hydrochloride